Mineralys Therapeutics Inc (NASDAQ: MLYS) kicked off on Tuesday, up 86.43% from the previous trading day, before settling in for the closing price of $15.48. Over the past 52 weeks, MLYS has traded in a range of $8.24-$18.38.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -170.42%. While this was happening, its average annual earnings per share was recorded 26.97%. With a float of $42.81 million, this company’s outstanding shares have now reached $65.73 million.
Mineralys Therapeutics Inc (MLYS) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Mineralys Therapeutics Inc is 35.42%, while institutional ownership is 73.86%. The most recent insider transaction that took place on Aug 13 ’25, was worth 146,987. In this transaction Chief Medical Officer of this company sold 11,365 shares at a rate of $12.93, taking the stock ownership to the 92,891 shares. Before that another transaction happened on Aug 13 ’25, when Company’s Officer proposed sale 11,365 for $12.93, making the entire transaction worth $146,987.
Mineralys Therapeutics Inc (MLYS) Latest Financial update
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -1.13 earnings per share (EPS), lower than consensus estimate (set at -0.83) by -0.3. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.65 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 26.97% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 6.59% during the next five years compared to -170.42% drop over the previous five years of trading.
Mineralys Therapeutics Inc (NASDAQ: MLYS) Trading Performance Indicators
Take a look at Mineralys Therapeutics Inc’s (MLYS) current performance indicators. Last quarter, stock had a quick ratio of 15.12.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.57, a number that is poised to hit -0.65 in the next quarter and is forecasted to reach -2.77 in one year’s time.
Technical Analysis of Mineralys Therapeutics Inc (MLYS)
The latest stats from [Mineralys Therapeutics Inc, MLYS] show that its last 5-days average volume of 3.78 million was superior to 0.97 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 83.81%.
During the past 100 days, Mineralys Therapeutics Inc’s (MLYS) raw stochastic average was set at 93.50%, which indicates a significant increase from 92.71% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.43 in the past 14 days, which was higher than the 0.94 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.44, while its 200-day Moving Average is $13.26. Now, the first resistance to watch is $32.00. This is followed by the second major resistance level at $35.14. The third major resistance level sits at $40.14. If the price goes on to break the first support level at $23.86, it is likely to go to the next support level at $18.86. The third support level lies at $15.72 if the price breaches the second support level.
Mineralys Therapeutics Inc (NASDAQ: MLYS) Key Stats
The company with the Market Capitalisation of 1.91 billion has total of 66,295K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -177,810 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -43,270 K.
